This paper reviews the use of stereotactic body radiotherapy (SBRT) for the treatment of renal cell carcinoma (RCC), and was presented at the Society of Urologic Oncology (SUO) in Washington last week.
- RCC is radiosensitive and SBRT can be used to stabilise or manage the symptoms of primary tumours
- SBRT may be useful as a supplementary treatment (adjunct) for the management of locally advanced disease, such as inferior vena cava tumour thrombus
- SBRT for metastases may stabilise disease and delay or obviate the need for additional systematic therapy
- SBRT is a palliative option and may be used to enhance the response to immunotherapy.